VKTX Hits Milestone: VK2735 Phase 3 Obesity and Diabetes Trial Completes Enrollment Ahead of Key 2026 Data
Viking Therapeutics Pushes Forward with Next-Generation Obesity Treatments
Viking Therapeutics (NASDAQ: VKTX) has reached a crucial inflection point with the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial for VK2735, a dual GLP-1/GIP receptor agonist. The study, which is now fully enrolled with approximately 1,000 adults struggling with obesity and type 2 diabetes, sets the stage for key efficacy and safety data on the biotech’s flagship pipeline asset.
What Makes VANQUISH-2 Stand Out?
VANQUISH-2 is a large, multicenter, randomized, double-blind, placebo-controlled trial evaluating VK2735 via subcutaneous injection, dosed once weekly for 78 weeks. This design aims to provide clear evidence of VK2735’s impact on reductions in body weight, as well as its safety profile across four treatment arms (7.5 mg, 12.5 mg, 17.5 mg, and placebo).
Primary Endpoint: Percentage change in body weight from baseline at 78 weeks.
Key Secondary/Exploratory Endpoints: Proportion of patients achieving weight loss endpoints (=5%, =10%, =15%, =20%).
| Trial Characteristic | Details |
|---|---|
| Participants | ~1,000 adults with obesity and type 2 diabetes |
| Design | Randomized, double-blind, placebo-controlled (4 arms) |
| Treatment Duration | 78 weeks + 52-week extension |
| Doses | 7.5 mg, 12.5 mg, 17.5 mg, placebo (weekly) |
| Primary Outcome | % Change in body weight vs. placebo at 78 weeks |
Past Successes Signal Confidence in VK2735's Potential
The optimism for VK2735 isn’t ungrounded. In 2024, the Phase 2 VENTURE trial demonstrated statistically significant reductions in mean body weight—up to 14.7%—over just 13 weeks for participants on VK2735, with safety and tolerability comparable to placebo. This strong efficacy profile, along with balanced discontinuation rates and mostly mild or moderate adverse events, set a high bar for VK2735 going into Phase 3.
Competitive Landscape: VK2735 Seeks to Join Elite Company
GLP-1 receptor agonists (like Ozempic®, Wegovy®, Rybelsus®) and dual GLP-1/GIP agonists (like Mounjaro®/Zepbound®) have transformed obesity and diabetes care. VK2735, as a next-generation, dual-action medication, is positioned to compete in a space where patient and clinical enthusiasm is high—highlighted by rapid enrollment in both VANQUISH-1 (completed November 2025) and VANQUISH-2 trials.
Pipeline Momentum: Data Catalysts on the Horizon
Investors and patients watching VKTX should also note:
- Phase 3 VANQUISH-1 obesity trial: Enrollment finished in November 2025; results expected in 2027.
- Phase 1 study on maintenance regimens: Results due Q3 2026.
- Viking’s oral VK2735 and other metabolic programs, including VK2809 and VK0214, add to the company’s momentum and optionality in the metabolic disorder space.
What to Watch: Significant Milestone, But Key Data Lies Ahead
While the completion of VANQUISH-2 enrollment doesn’t guarantee clinical or commercial success, it signals tangible progress for VKTX and growing medical interest in weight-loss alternatives. The company now looks ahead to pivotal data readouts in 2026 and 2027 that could define VK2735’s future in a fiercely competitive landscape.
Investors and healthcare observers should keep an eye on how VK2735’s results stack up against leading GLP-1/GIP drugs. Efficacy, safety, route of administration, and long-term durability will be critical—especially as patient demand continues to outpace current options. With milestone after milestone hit, VKTX is firmly on the radar as a clinical-stage innovator in obesity and metabolic treatment.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI